TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Abstract

Takeda Global Research and Development.

Full Text

DOI - Lancet (DOI)
Swets Information Services - full-text online
OhioLINK Electronic Journal Center - full-text online
Elsevier Science - full-text online
EBSCO - full-text online

Subjects

Similar articles

Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. (2013-04-25)
The placebo response in clinical trials-the current state of play. (2013-01-18)
Variability in placebo analgesia and the role of fear of pain--an ERP study. (2011-09-29)
Mechanisms of placebo and placebo-related effects across diseases and treatments. (2008-01-10)
Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. (2009-08-31)
Expectations of analgesia do not affect spinal nociceptive R-III reflex activity: an experimental study into the mechanism of placebo-induced analgesia. (2001-01-26)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. (2013-02-08)
Placebo response in clinical trials with schizophrenia patients. (2011-02-02)
New insights into the placebo and nocebo responses. (2008-07-31)
Listening to placebo in clinical trials for female sexual dysfunction. (2012-10-04)

Authors

Publication date

2012-04-16

Journal

Lancet
Lancet (1474-547X)

Journal topics

Language

Eng.

Copyright

Lancet

Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA. burantc [at] umich.edu

Release reference

Lancet. 2012 Apr;379(9824):1403-11

Related books

Español | English

© Galenicom 1999-2013